Gender Dysphoria in Transgender Men Transgender men, Testosterone, Testosterone Undecanoate, Testosterone Enanthate, Metabolic, Cardiovascular disease, Lipids
Conditions
Interventions
Intramuscular testosterone enanthate administered 100 mg every 2 weeks ,Intramuscular testosterone undecanoate administered 10000 mg single dose
Active Comparator Drug,Active Comparator Drug
Testosterone Enanthate,Testosterone Undecanoate
Sponsors
Ratchadapisek Research Fund, Faculty of Medicine, Chulalongkorn University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 40 years. 2.Diagnosed with gender dysphoria at King Chulalongkorn Memorial Hospital or has a medical certificate from another institution. 3.Planning to initiate testosterone therapy and has never received testosterone treatment before. 4.Able to understand and communicate in Thai. 5.Willing to participate and able to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1.Contraindications to testosterone therapy, including pregnancy, cardiovascular disease, cerebrovascular disease, deep vein thrombosis, pulmonary embolism, breast cancer, endometrial cancer, or obstructive sleep apnea. 2.Current use of medications affecting metabolic outcomes (e.g., lipid-lowering drugs or antidiabetic medications). 3.History of allergy to testosterone. 4.Abnormal vaginal bleeding. 5.Contraindications to intramuscular injection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HDL cholesterol level changes 13 weeks mg/dL HDL cholesterol level changes | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in metabolic parameters 13 weeks LDL cholesterol, total cholesterol, triglycerides, plasma glucose blood tests.,Changes in serum hormone levels 13 weeks serum testosterone and estradiol levels | — |
Countries
Thailand
Contacts
Public ContactNattaporn Titapant
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed